Evidence map›Paper›PMID 39072442›Full record

ArticleFuture oncology (London, England)2024

Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.

Lucia Masarova, Srdan Verstovsek, Tom Liu, Sumati Rao, Gautam Sajeev, Mirko Fillbrunn, Ryan Simpson, Weilong Li, Joseph Yang, Yvette Le Lorier and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lucia MasarovaDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer, Houston, TX 77030, USA.ORCID 0000-0002-3836-7356
Srdan VerstovsekDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer, Houston, TX 77030, USA.
Tom LiuGSK plc, Philadelphia, PA 19104, USA.
Sumati RaoGSK plc, Philadelphia, PA 19104, USA.
Gautam SajeevAnalysis Group, Boston, MA 02199, USA.
Mirko FillbrunnAnalysis Group, Boston, MA 02199, USA.
Ryan SimpsonAnalysis Group, Boston, MA 02199, USA.
Weilong LiAnalysis Group, Boston, MA 02199, USA.
Joseph YangGSK plc, Philadelphia, PA 19104, USA.
Yvette Le LorierGSK plc, Philadelphia, PA 19104, USA.
Boris GorshGSK plc, Philadelphia, PA 19104, USA.
James SignorovitchAnalysis Group, Boston, MA 02199, USA.

Funding

GSK plc
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BenzamidesBlood TransfusionDanazolPrimary MyelofibrosisPyrimidinesAnemiaHumansBenzamidesDanazolN-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamidePyrimidinesACVR1anemiacostdanazolJAK inhibitormomelotinibmyelofibrosistime burdentransfusion

Identifiers

PMID39072442
PMCPMC11508939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.